论文部分内容阅读
目的探讨肝纤维化指标联合检测在肝病中的应用价值。方法采用放免法对144例肝病患者进行IV－C、HA、LN检测，并与30例献血员作对照组．统计学处理采用t检验和X2检验。结果重症肝炎、肝炎肝硬化血清IN-C、HA和LN水平和慢性肝炎（中、重度）患者血清IV—C和HA较对照组均明显升高（P＜0．001），肝硬化较慢性肝炎（中、重度）3项肝纤维化指标明显升高（P＜0．05）。肝硬化、重型肝炎和慢性肝炎（中、重度）3项指标同时检出率分别为88．9％、80％和70．8％。结论血清W—C、HA、LN联合检测对肝病的诊断及预后的判断有重要意义。病毒性肝炎患者肝纤维化血清学指标3项同时超过正常上限时，即应抗肝纤维化治疗。
Objective To investigate the value of combined detection of liver fibrosis in liver disease. Methods Radioimmunoassay was used to detect IV-C, HA and LN in 144 patients with liver disease, and 30 donors were used as control group. Statistical analysis using t test and X2 test. Results Serum levels of IV-C and HA in patients with severe hepatitis and cirrhosis of liver cirrhosis and chronic hepatitis (moderate and severe) were significantly higher than those in control group (P <0.001), chronic cirrhosis Hepatic (moderate and severe) three indicators of liver fibrosis was significantly increased (P <0.05). The simultaneous detection rates of cirrhosis, severe hepatitis and chronic hepatitis (moderate and severe) were 88.9%, 80% and 70.8% respectively. Conclusion Serum W-C, HA, LN joint detection of liver disease diagnosis and prognosis of great significance. Viral hepatitis patients with liver fibrosis serological indicators 3 while more than the normal upper limit, that should be anti-liver fibrosis treatment.